<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Amyloid forms within pancreatic islets in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> from aggregates of the β-cell <z:chebi fb="7" ids="16670">peptide</z:chebi> islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (IAPP) </plain></SENT>
<SENT sid="1" pm="."><plain>These aggregates are toxic to β-cells, inducing β-cell <z:hpo ids='HP_0011420'>death</z:hpo> and dysfunction, as well as inciting islet <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The β-cell is subject to a number of other stressors, including <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, that may contribute to amyloid formation by increasing IAPP production by the β-cell. β-Cell dysfunction, evident as impaired <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion and defective prohormone processing and exacerbated by metabolic stress, is also a likely prerequisite for islet amyloid formation to occur in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Islet transplants in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> face similar stressors, and are subject to rapid amyloid formation and impaired proinsulin processing associated with progressive loss of β-cell function and mass </plain></SENT>
<SENT sid="4" pm="."><plain>Declining β-cell mass is predicted to increase metabolic demand on remaining β-cells, promoting a feed-forward cycle of β-cell decline </plain></SENT>
</text></document>